A clinical study of safety and efficacy of intracameral Phenocaine in phacoemulsification cataract surgery

Background: Cataract is the biggest cause of curable blindness in India & worldwide.Cataract extraction is the most effective surgical intervention in terms of quality of life restored. Phacoemulsification has led to substantial decrease in duration of surgery, postoperative course and duration of hospitalization. However obtaining aqeduate, quick, stable mydriasis and anesthesia is one of the key points influencing the safety of surgery and patients comfort.Mydriatic eyedrops is the standard method for pupil dilatation.An alternative to the traditional preparation for cataract surgery is a complex drug containing mydriatics and analgesics: Phenocaine plus (entod pharma) mixture of 0.2 mg tropicamide, 0.31mg phenylephrine, and 10 mg lidocaine.The present study is undertaken to study the safety and efficacy of intracameral mydriasis by phenocaine plus in phacoemulsification cataract surgery.Materials and Methods: Single centre, prospective observational study was done over a period of 18 months between 1st March 2021 to 31st August 2022. 200 patients underwent phacoemulsification under intracameral phenocaine plus were prospectively evaluated for grade of mydriasis, pain outcome, clinical outcome and also patients and surgeon satisfaction through questionnaire. Patients with History of previous ocular co morbidities, injury or surgery, who are unable to understand pain scale, Traumatic cataract, congenital cataract, complicated cataract, Patients with Pxf (pseudoexfoliation syndrome) were excluded from the study.Results: Out of 200 patients who underwent phacoemulsification, 66.5% had mild pain and 33.5% had No pain, during the administration of intracameral mydriatics. 4 hours post operatively, 71% of the respondents had mild pain and 29% had No pain. 69% had